Veristat, a full service Clinical Research Organization (CRO), announced today the signing of a Preferred Provider Agreement (PPA) with Aegerion Pharmaceuticals Inc. (“Aegerion”), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Veristat has assisted Aegerion with US Food and Drug Administration, EU Market Authorization Application, and Japan Food and Drug Administration submission projects over the past 5 years.
Veristat Continues To Be Recognized for Its Positive Impact & Company Growth
SOUTHBOROUGH, MA – August 17, 2016 – Veristat announced today that it has been recognized once again by Inc. Magazine as one of America’s fastest-growing private companies. Veristat debuted on the list in 2015.
Two of Veristat’s statistical and adaptive design experts submitted a research paper which was published in the June 2016 issue of the Journal of Bioanalysis & Biostatistics.
Accelerates Hiring & Plans to Open Office in Raleigh-Durham, North Carolina
Appoints Mark Chang as Senior Vice President of Strategic Statistical Consulting
SOUTHBOROUGH, MA – June 15, 2016 – Veristat, a full service Clinical Research Organization (CRO), announced that it has strengthened its statistical consulting and adaptive design expertise with the appointment of Mark Chang, PhD to the newly created position of Senior Vice President of Strategic Statistical Consulting. Dr. Chang will help clients evaluate and implement strategic, operational and technical efficiencies to advance products through the clinical trial and regulatory submission process.
SOUTHBOROUGH, MA – May 2, 2016 – Veristat, a full service Clinical Research Organization (CRO), announced today that it is expanding its clinical research offerings into Europe through the acquisition of UK-based CRO, Spero Oncology. Spero Oncology is a UK-based CRO specializing in providing clinical operations support for oncology clinical trials primarily throughout Europe, but also in Australia and New Zealand. With the acquisition of Spero Oncology, Veristat now offers its clients full clinical operations support in Europe including feasibility studies, legal representation in the European Union, Clinical Monitoring, Project Management, Protocol Writing and Regulatory Strategy.
Veristat Recognized as One of the Top 50 Fastest-Growing Private Companies in Massachusetts
Veristat, a full service Clinical Research Organization (CRO), announced today that it has been recognized as one of the top 50 fastest-growing private companies in Massachusetts, taking the #35 slot. According to Privco[i], there are over 4,000 private firms operating in Massachusetts today.
Veristat joins the Boston Business Journal’s 2016 Fast 50 (Formerly Pacesetters) list. This is the list of the fastest growing private companies in Massachusetts.
SOUTHBOROUGH, MA – March 08, 2016 – Veristat, a full service Clinical Research Organization (CRO), announced today the appointment of Faith Haines Kolb to the newly created position Vice President of Biometrics. Faith joins Veristat with over 20 years of experience leading operational teams and large-scale projects during periods of rapid growth and international expansion for both large and small CROs. As Vice President of Biometrics, Faith will lead and continue to grow the Biostatistics and Programming teams, as well as the Data Management and Data Standards groups at Veristat.
Veristat Raises over $20,000 to Support Rare Cancer Research
On Saturday, February 27th, Team Veristat JOINED THE BATTLE with Cycle for Survival 2016! Team Veristat had riders at both the Boston, MA and Palo Alto, CA events. In Boston, over 900 riders participated in this amazing, fun and inspiring event! Across the country in 2016 alone, over twenty million dollars has been raised to fund rare cancer research.